 A SINGLE-DOSE, RANDOMIZED, TWO-PERIOD, TWO-TREATMENT, TWO-SEQUENCE, CROSSOVER BIOEQUIVALENCE STUDY ON A OLOSTAR TAB VERSUS TWO CO-ADMINISTERED REFERENCE PRODUCTS OLMESARTAN MEDOXOMIL AND ROSUVASTATIN CALCIUM IN HEALTHY VOLUNTEERS: 